Top

Huisarts en wetenschap

Gepubliceerd in:

01-05-2011 | NASCHOLING

Targeted therapieën tegen kanker

Auteurs: prof.dr. E. Boven, prof.dr. G.J. Ossenkoppele

Gepubliceerd in: Huisarts en wetenschap | Uitgave 5/2011

Samenvatting

Boven E, Ossenkoppele GJ. Targeted therapieën tegen kanker. Huisarts Wet 2011;54(5):266–71.

Er zijn de afgelopen jaren veel nieuwe medicijnen tegen kanker op de markt gekomen die specifieke signaleringsroutes in tumorcellen gericht blokkeren. Naast deze zogeheten ‘targeted’ therapieën is ook een aantal oude kankermedicijnen in een nieuw jasje gestoken, waardoor zij gemakkelijker kunnen worden toegediend of minder bijwerkingen hebben. De nieuwe therapieën hebben de overleving van kankerpatiënten sterk verbeterd, en huisarts zal deze nieuwe of vernieuwde geneesmiddelen dan ook vaker dan vroeger tegenkomen in de dagelijkse praktijk. Dit nascholingsartikel schetst het werkingsmechanisme van de targeted therapieën, geeft een globaal overzicht wanneer en bij welke tumoren zij worden ingezet en laat zien welke bijwerkingen de huisarts zou kunnen tegenkomen.

vorige artikel Patiënten over telefonische bereikbaarheid

volgende artikel Patiëntgericht communiceren bij claimend gedrag

Cilloni D, Saglio G. CML: A model for targeted therapy. Best Pract Res Clin Haematol 2009;22:285–94.PubMedCrossRef

Goldman JM. Treatment strategies for CML. Best Pract Res Clin Haematol 2009; 22:303–13.PubMedCrossRef

Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E. Applications of monoclonal antibodies for the treatment of hematological malignancies. Expert Opin Biol Ther 2009;9:207–20.PubMedCrossRef

Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009;8:223–35.PubMedCrossRef

Van Meerten T, Hagenbeek A. CD20-targeted therapy: A breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med. 2009;67:251–9.PubMed

Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 2009;23:2222–32.PubMedCrossRef

Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia. 2009;23:1964–79.PubMedCrossRef

Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550–65.PubMedCrossRef

Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 2010;277:301–8.PubMedCrossRef

10.

Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 2010;277:309–15.PubMedCrossRef

11.

Chau I, Cunningham D. Treatment in advanced colorectal cancer: What, when and how? Br J Cancer 2009;100:1704–19.PubMedCrossRef

12.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21–8.PubMedCrossRef

13.

Rukazenkov Y, Speake G, Marshall G, Anderton J, Davies BR, Wilkinson RW, et al. Epidermal growth factor receptor tyrosine kinase inhibitors. Similar but different? Anticancer Drugs 2009;20:856–66.PubMedCrossRef

14.

Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357–60.PubMedCrossRef

15.

Melosky B, Burkes R, Rayson D, Alcindor T, Shear N, Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies. Canadian recommendations. Current Oncol 2009;16:16–26.

16.

Pérez-Soler R, Delord JP, Halpern A, Kelly K, Sureda BM, Von Pawel J, et al. HER1/EGFR inhibitor-associated rash; future directions for management and investigation outcomes from HER1/EGFR inhibitor rash management forum. Oncologist 2005;10:345–56.PubMedCrossRef

17.

Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470–81.PubMedCrossRef

18.

Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27:5838–47.PubMedCrossRef

19.

Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor- 2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009;31:2332–48.PubMedCrossRef

20.

Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for inhibition. MAbs 2010;2:165–75.PubMedCrossRef

21.

Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;8:507–18.CrossRef

22.

Patel NS, Muneer A, Blick C, Arya M, Harris AL. Targeting vascular endothelial growth factor in renal cell carcinoma. Tumor Biol 2009;30:292–9.CrossRef

23.

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115–24.PubMedCrossRef

24.

Rini BI. Metastatic renal cell carcinoma: Many treatment options, one patient. J Clin Oncol 2009:27::3225–34.PubMedCrossRef

25.

Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8–18.PubMedCrossRef

26.

Aprile G, Mazzer M, Moroso S, Puglisi F. Pharmacology and therapeutic efficacy of capecitabine. Focus on breast and colorectal cancer. Anticancer Drugs 2009;20:217–29.PubMedCrossRef

27.

Comella P, Franco L, Casaretti R, De Portu S, Menditto E. Emerging role of capecitabine in gastric cancer. Pharmacotherapy 2009;29:318–30.PubMedCrossRef

28.

Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95–9.PubMedCrossRef

29.

O'Brien MER. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008;19:1–7.PubMedCrossRef

30.

Guarneri V, Piacentini F, Barbieri E, Conte PF. Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 2010;117:152–8.PubMedCrossRef

31.

Gossage L, Eisen T. Targeting multiple kinase pathways. Change in paradigm. Clin Cancer Res 2010;16:1973–8.PubMedCrossRef

32.

Ellis LM, Hicklin DJ. Resistance to targeted therapies: Refining anticancer therapy in the era of molecular oncology. Clin Cancer Res 2009;15:7471–8.PubMedCrossRef

33.

Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti- CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206–13.PubMedCrossRef

34.

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.PubMedCrossRef

35.

Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283–9.PubMedCrossRef

36.

Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, et al. Clinical cancer advances 2009: Major research advances in cancer treatment, prevention, and screening – a report from the American Society of Clinical Oncology. J Clin Oncol 2009;27:6052–69.PubMedCrossRef

Titel: Targeted therapieën tegen kanker
Auteurs: prof.dr. E. Boven
prof.dr. G.J. Ossenkoppele
Publicatiedatum: 01-05-2011
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Huisarts en wetenschap / Uitgave 5/2011
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI: https://doi.org/10.1007/s12445-011-0135-7

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 5/2011

Verantwoorde zorg?

Duizelige duikelaar ook brekebeen?

Huisarts of ketenzorg: wat wilde de diabetespatiënt?

Patiëntgericht communiceren bij claimend gedrag

Kerende kansen

Richtlijnen in de spreekkamer, van dogma naar dans